NCT01518387 is a Phase 3 clinical trial of Lanthanum Carbonate (BAY77-1931) in Hyperphosphatemia, sponsored by Bayer.

Who is sponsoring NCT01518387?

NCT01518387 is sponsored by Bayer.

What drugs are being tested in NCT01518387?

Interventions in NCT01518387: Lanthanum Carbonate (BAY77-1931).

What condition does NCT01518387 study?

NCT01518387 studies Hyperphosphatemia.

Is NCT01518387 still recruiting?

NCT01518387 is currently completed. Last updated 10 March 2016.

Last reviewed 2016-03-10 · How we verify

NCT01518387

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD)

Completed Phase 3 Last updated 10 March 2016

What this trial tests

Phase 3 trial testing Lanthanum Carbonate (BAY77-1931) in Hyperphosphatemia in 43 participants. Completed in 1 July 2006.

Timeline

1 January 2006

Primary endpoint
1 July 2006

1 July 2006

Quick facts

Lead sponsor	Bayer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	1 January 2006
Primary completion	1 July 2006
Estimated completion	1 July 2006
Sites	11 locations across Japan

Drugs / interventions tested

Lanthanum Carbonate (BAY77-1931) — full drug profile →

Conditions studied

Hyperphosphatemia — all drugs for Hyperphosphatemia →

Sponsor

Bayer — full company profile →

Who can join

Adults 20 to 75, any sex, with Hyperphosphatemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from baseline in serum phosphate levels at the end of the treatment period
Time frame: Baseline to Week 8

Sponsor's own description

The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hyperphosphatemia

Currently open trials in the same condition.

NCT06933472 — A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China · Phase 3 · recruiting
NCT06664125 — Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemi · Phase 2 · recruiting
NCT06206135 — Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule · recruiting
NCT06186934 — Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients · recruiting
NCT03573089 — Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE) · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01518387 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 10 March 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01518387.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing